ReviewMolecular biology reports2026
Autophagic therapeutic targeting for Doxorubicin-induced cardiomyopathy.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy has been extensively studied in a variety of pathologies, including neurological disorders, cancers, muscle diseases, aging, and cardiovascular diseases. Doxorubicin (Dox) is a potent anticancer drug widely used to treat various cancers. Despite its therapeutic benefits, it has cardiotoxic side effects, interfering with its clinical application. Dox-induced cardiomyopathy (DIC) is one of the most prominent and lethal side effects associated with the use of Dox. Numerous investigations have revealed that Dox administration impacts autophagy; however, the precise mechanism by which Dox modifies this process remains unclear, as the role of autophagy in heart tissue is controversial, ranging from being cytoprotective to cytotoxic. Various therapeutic interventions, including pharmacological drugs and natural products, have been reported to influence the autophagic flux in DIC. In this review, we explore the therapeutic potential of autophagy modulation in DIC, focusing on how various pharmacological drugs and natural products influence autophagy to mitigate cardiac damage. This review uniquely emphasizes the mechanistic role of autophagy in DIC and provides a comprehensive analysis of therapeutic interventions targeting autophagy as a strategy for cardioprotection.
Indexed as
Identifiers
42377651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.